Loading clinical trials...
Loading clinical trials...
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
Conditions
Interventions
LY4584180
Rituximab
Locations
45
United States
Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California, United States
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
University of Miami - Sylvester Cancer Center
Miami, Florida, United States
Start Date
April 1, 2026
Primary Completion Date
February 1, 2027
Completion Date
December 1, 2029
Last Updated
April 17, 2026
NCT07545603
NCT06337318
NCT05006716
NCT06026319
NCT07128641
NCT06510361
Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions